<DOC>
	<DOCNO>NCT01118624</DOCNO>
	<brief_summary>The purpose study determine efficacy ( ability provide beneficial treatment disease ) pralatrexate treatment female patient advance metastatic breast cancer fail prior chemotherapy . Patients receive vitamin B12 folic acid supplementation .</brief_summary>
	<brief_title>Study Pralatrexate Female Patients With Previously-treated Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>HER2 negative advance metastatic breast cancer Disease become bad least 1 prior chemotherapy regimen advance metastatic disease Advanced metastatic disease resistant taxane anthracyclinecontaining chemotherapy regimen , resistant taxanes anthracycline therapy indicate Patients control brain metastasis must finish receive radiation therapy corticosteroid , stable taper dose â‰¤ 10 mg/day prednisone equivalent least 28 day prior study entry Measurable disease Female 18 year age old Performance status less equal 2 Life expectancy 3 month Blood , liver kidney laboratory test result meet protocol requirement Patients must negative serum pregnancy test within 14 day enrollment agree use medically acceptable effective birth control enrollment least 30 day last dose pralatrexate . Patients postmenopausal least 1 year ( 12 month since last menses ) surgically sterilize require test . Willing attend visit repeat dose follow Give write informed consent Patients bone metastasis Patients single metastatic site without histological proof lesion metastatic breast cancer Patients inflammatory breast cancer Treatment systemic chemotherapy , hormone therapy , radiation therapy , investigational therapy within 3 week ( 6 week nitrosoureas , mitomycin C ) prior enrollment , except follow : Bisphosphonates , ongoing Prior treatment methotrexate Prior treatment antiangiogenics within 6 month prior enrollment Have receive 2 prior chemotherapy regimen ( 3 one treatment neoadjuvant adjuvant chemotherapy ) Have previously receive pralatrexate Have receive allow maximum total dose anthracycline Prior radiation therapy 30 % bone marrow reserve prior bone marrow/stem cell transplantation Congestive heart failure Class III/IV Uncontrolled hypertension ( high blood pressure ) Active infection serious medical condition , would impair ability patient receive protocol treatment Females pregnant breastfeed Major surgery within 14 day enrollment Another active cancer addition advance metastatic breast cancer , except well treat situ cervical cancer basal cell skin cancer Dementia alter mental status would prevent patient understand give informed consent limit ability follow study requirement Patients human immunodeficiency virus ( HIV ) positive CD4 count le 100 mm3 detectable viral load within past 3 month receive antiretroviral therapy Patients hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) detectable viral load immunological evidence chronic active disease receiving/requiring antiviral therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Female</keyword>
	<keyword>Advanced</keyword>
	<keyword>Metastatic</keyword>
</DOC>